PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2011.43.3.1482011433148-153Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric CancerEun Kyoung Jeon, Sook Hee Hong, Tae Hee Kim, Seung Eun Jung, Ji Chan Park, Hye-Sung Won, Yoon-Ho Ko, Sang Young Rho, Young Seon Honghttp://www.e-crt.org/upload/pdf/crt-43-148.pdf, http://www.e-crt.org/upload/pdf/crt-43-148.pdf
Annals of Oncology10.1016/s0923-7534(20)30178-2201223iv38P-0025 Modified Folfiri (mFolfiri) as Second Line Chemotherapy in Advanced Gastric Cancer (AGC)Arslane Rahal, Valerie Boige, Malka David, Chahinez Rahal, Pascal Burtin, Isabelle Sinapi, Dominique Elias, Diane Goere, Benjamin Lacas, Michel Ducreuxhttps://api.elsevier.com/content/article/PII:S0923753420301782?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420301782?httpAccept=text/plain
Gastroenterology10.1016/s0016-5085(13)61922-820131445S-519Su1959 Efficacy and Safety of FOLFIRI After Failure of FOLFOX-4 in Advanced Gastric CancerMoo In Park, Seun Ja Park, Won Moon, Hyung Hun Kim, Hae-Won Leehttps://api.elsevier.com/content/article/PII:S0016508513619228?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508513619228?httpAccept=text/plain
Cancer Medicine10.1002/cam4.451220211141088-1098Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysisShun Tezuka, Makoto Ueno, Ritsuko Oishi, Shuhei Nagashima, Yusuke Sano, Kuniyuki Kawano, Satoshi Tanaka, Taito Fukushima, Hiroyuki Asama, Naoki Konno, Satoshi Kobayashi, Manabu Morimoto, Shin Maedahttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4512, https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cam4.4512, https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4512
Annals of Oncology10.1093/annonc/mdx261.077201728iii34A randomized trial of FOLFIRI versus docetaxel and cisplatin as a second-line chemotherapy after failure of first-line chemotherapy in advanced gastric cancerKil Lee Sang, Seok Moon Hee, Eun Kim Sung, seok jang jin, Young Cho Joo, Sun Kim Eun, Hyung Lee Si, Chul Park Jun, Kang Lee Yonghttps://api.elsevier.com/content/article/PII:S0923753419658606?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419658606?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_3/mdx261.077/18107404/mdx261.077.pdf
The Korean Journal of Gastroenterology10.4166/kjg.2015.66.1.120156611Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric CancerSung Chul Park, Hoon Jai Chunhttps://synapse.koreamed.org/DOIx.php?id=10.4166/kjg.2015.66.1.1, https://synapse.koreamed.org/pdf/10.4166/kjg.2015.66.1.1, http://synapse.koreamed.org/DOIx.php?id=10.4166/kjg.2015.66.1.1
Annals of Oncology10.1016/j.annonc.2022.04.142202233S265P-52 FOLFIRI or FOLFOX in second line of advanced biliary tract cancer: A retrospective analysisM. Balarine, T. Felismino, M. Camandarobahttps://api.elsevier.com/content/article/PII:S0923753422008328?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753422008328?httpAccept=text/plain
Annals of Oncology10.1016/s0923-7534(20)33273-7201223ix233A Multi-Center Phase II Study and Predictive Biomarker Analysis of Combined Cetuximab and Modified Folfiri as Second-Line Treatment in Patients with Metastatic Gastric CancerL. Jinhttps://api.elsevier.com/content/article/PII:S0923753420332737?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420332737?httpAccept=text/plain
The Lancet Oncology10.1016/s1470-2045(21)00211-42021227e284Second-line FOLFOX chemotherapy for advanced biliary tract cancerFangqiang Weihttps://api.elsevier.com/content/article/PII:S1470204521002114?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1470204521002114?httpAccept=text/plain
British Journal of Cancer10.1038/sj.bjc.66053742009101101658-1663A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerC Yoo, J Y Hwang, J-E Kim, T W Kim, J S Lee, D H Park, S S Lee, D W Seo, S K Lee, M-H Kim, D J Han, S C Kim, J-L Leehttp://www.nature.com/articles/6605374.pdf, http://www.nature.com/articles/6605374, http://www.nature.com/articles/6605374.pdf